This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.38 in the latest trading session, marking a -1.25% move from the prior day.
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
by Zacks Equity Research
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
Can Q1 Earnings Lift Healthcare ETFs Higher?
by Sweta Killa
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Here Are the Key Takeaways From J&J's Q1 Earnings Report
by Zacks Equity Research
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
Wave Life Sciences Plunges After DMD Study Data Readout
by Zacks Equity Research
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
by Zacks Equity Research
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Dow 30 Stock Roundup: Procter & Gamble Hikes Dividend, Boeing Q1 Commercial Deliveries Fall
by Swarup Gupta
The index traversed a lackluster trading week as investors looked toward first-quarter earnings numbers for direction.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $42.73, moving -0.26% from the previous trading session.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
by Kinjel Shah
Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval
by Swarup Gupta
The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.74, marking a -0.23% move from the previous day.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Royal Dutch, Celgene, Advanced Micro and Blackstone
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Why the Earnings Surprise Streak Could Continue for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top Research Reports for Pfizer, Royal Dutch Shell & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Royal Dutch Shell (RDS.A) and Celgene (CELG).
Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics
by Zacks Equity Research
Novartis (NVS) is set to acquire IFM Tre, a subsidiary of IFM Therapeutics LLC, and strengthen its pipeline of drugs for chronic inflammatory disorders.
Spero Gets Fast Track Designation for SPR994, Shares Improve
by Zacks Equity Research
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.